Cancer induced cachexia, a gross loss of skeletal muscle with or without adipose tissue wasting, remains a clinical impasse resulting in poor prognosis and Quality of Life (QoL). It is characterized by an inflammation...Cancer induced cachexia, a gross loss of skeletal muscle with or without adipose tissue wasting, remains a clinical impasse resulting in poor prognosis and Quality of Life (QoL). It is characterized by an inflammation driven anorexia and aberrant energy and protein balance. Indubitably, nutritional rehabilitation is required to address various daunting challenges of this multifactorial syndrome. Esperer Onco Nutrition has come up with an optimal clinical nutrition formulation with promising anti-cachexia effects. Towards validating the efficacy and ensuring the safety of EON Therapy (Es-Invigour plus Es-Fortitude-Protect) under clinical settings, a phase IV post marketing surveillance (PMS) study with 63 patients from various hospitals across India was undertaken. This multi-nutrient and multi-targeted nutritional intervention, being concurrent with mainstream therapy, demonstrated potential to ameliorate the cachectic condition which was measured by body weight of the volunteers at each visit. Biochemical parameters improved or remained same. Overall QoL assessment was performed by using ECOG Scale and Malnutrition Screening Tool (MST) which showed significant improvement in physical wellness and nutritional status of the volunteers. No adverse effect was observed during the entire period. These observations reinforce the need of research based nutritional intervention for clinical use in cachectic cancer patients.展开更多
文摘Cancer induced cachexia, a gross loss of skeletal muscle with or without adipose tissue wasting, remains a clinical impasse resulting in poor prognosis and Quality of Life (QoL). It is characterized by an inflammation driven anorexia and aberrant energy and protein balance. Indubitably, nutritional rehabilitation is required to address various daunting challenges of this multifactorial syndrome. Esperer Onco Nutrition has come up with an optimal clinical nutrition formulation with promising anti-cachexia effects. Towards validating the efficacy and ensuring the safety of EON Therapy (Es-Invigour plus Es-Fortitude-Protect) under clinical settings, a phase IV post marketing surveillance (PMS) study with 63 patients from various hospitals across India was undertaken. This multi-nutrient and multi-targeted nutritional intervention, being concurrent with mainstream therapy, demonstrated potential to ameliorate the cachectic condition which was measured by body weight of the volunteers at each visit. Biochemical parameters improved or remained same. Overall QoL assessment was performed by using ECOG Scale and Malnutrition Screening Tool (MST) which showed significant improvement in physical wellness and nutritional status of the volunteers. No adverse effect was observed during the entire period. These observations reinforce the need of research based nutritional intervention for clinical use in cachectic cancer patients.
